A lead-in safety study followed by a phase 2 clinical trial of dabrafenib, trametinib and hydroxychloroquine in advanced BRAFV600 mutant melanoma patients previously treated with BRAF-/MEK-inhibitors and immune checkpoint inhibitors

Onderzoeksoutput: Articlepeer review

6 Citaten (Scopus)

Vingerafdruk

Duik in de onderzoeksthema's van 'A lead-in safety study followed by a phase 2 clinical trial of dabrafenib, trametinib and hydroxychloroquine in advanced BRAFV600 mutant melanoma patients previously treated with BRAF-/MEK-inhibitors and immune checkpoint inhibitors'. Samen vormen ze een unieke vingerafdruk.

Medicine & Life Sciences